In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.
List view / Grid view
Filter the results
As the global COVID-19 situation is rapidly changing, staying abreast with the latest news can be challenging. In this article, Sheraz Gul provides an overview of the broad range of potential treatments in development and discusses how the regulatory landscape can shift at any time.
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
Researchers have developed a molecule that can restore lost connections in the spinal cords and brains of mice with cerebellar ataxia, Alzheimer's disease and spinal cord injury.
By targeting a previously undiscovered allosteric site on a DMD-associated enzyme, researchers found muscle cell conditions improved.
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
Following their success in organoid systems, two drug candidates are now to be administered to ferrets and tested against COVID-19.
Researchers have found a nanobody named Ty1 that neutralises SARS-CoV-2 by attaching itself to the Spike protein of COVID-19.
Scientists have shown that a Selenium-based drug-molecule called ebselen and other novel compounds can delay ALS onset in mouse models.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
Scientists have patented their technique of inhibiting cellular growth factor signalling to stop SARS-CoV-2 replication and treat COVID-19.
The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.
Researchers have discovered compounds able to restart production of VEGF-A in cellular models, which rebuilds blood vessels and muscle in damaged heart tissue.
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
Researchers reveal their antibiotics disrupt the bacterial TonB system which uropathogenic E. coli (UPEC) uses to uptake iron in order to cause urinary tract infections.